Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorena Landuzzi

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Translational Lung Cancer Research|December 15, 2022
ADK-VR2, a cell line derived from a treatment-naïve patient with <i>SDC4-ROS1</i> fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLCFrancesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, et al.
Cancer Research|December 14, 2021
Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 SarcomaMarianna Carrabotta, Maria Antonella Laginestra, Giorgio Durante, et al.
Breast Cancer Research : BCR|January 24, 2014
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2Carla De Giovanni, Giordano Nicoletti, Elena Quaglino, et al.
Biomedicines|October 27, 2022
Prevention and Therapy of Metastatic HER-2<sup>+</sup> Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle VaccineFrancesca Ruzzi, Arianna Palladini, Stine Clemmensen, et al.
Scientific Reports|August 23, 2019
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigationsPatrizia Nanni, Lorena Landuzzi, Maria Cristina Manara, et al.
Oncotarget|September 15, 2017
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic responseArianna Palladini, Giordano Nicoletti, Alessia Lamolinara, et al.
Oncoimmunology|February 6, 2018
Virus-like particle display of HER2 induces potent anti-cancer responsesArianna Palladini, Susan Thrane, Christoph M Janitzek, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 7, 2025
Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcomaMaria Cristina Manara, Francesca Bruzzese, Laura Formentini, et al.
Scientific Reports|January 16, 2021
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograftLorena Landuzzi, Arianna Palladini, Claudio Ceccarelli, et al.
The International Journal of Biological Markers|September 30, 2009
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysisAngelo Paradiso, Anita Mangia, Claudio Orlando, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Translational Lung Cancer Research|December 15, 2022
ADK-VR2, a cell line derived from a treatment-naïve patient with <i>SDC4-ROS1</i> fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLCFrancesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, et al.
Cancer Research|December 14, 2021
Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 SarcomaMarianna Carrabotta, Maria Antonella Laginestra, Giorgio Durante, et al.
Breast Cancer Research : BCR|January 24, 2014
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2Carla De Giovanni, Giordano Nicoletti, Elena Quaglino, et al.
Biomedicines|October 27, 2022
Prevention and Therapy of Metastatic HER-2<sup>+</sup> Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle VaccineFrancesca Ruzzi, Arianna Palladini, Stine Clemmensen, et al.
Scientific Reports|August 23, 2019
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigationsPatrizia Nanni, Lorena Landuzzi, Maria Cristina Manara, et al.
Oncotarget|September 15, 2017
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic responseArianna Palladini, Giordano Nicoletti, Alessia Lamolinara, et al.
Oncoimmunology|February 6, 2018
Virus-like particle display of HER2 induces potent anti-cancer responsesArianna Palladini, Susan Thrane, Christoph M Janitzek, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 7, 2025
Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcomaMaria Cristina Manara, Francesca Bruzzese, Laura Formentini, et al.
Scientific Reports|January 16, 2021
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograftLorena Landuzzi, Arianna Palladini, Claudio Ceccarelli, et al.
The International Journal of Biological Markers|September 30, 2009
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysisAngelo Paradiso, Anita Mangia, Claudio Orlando, et al.
Pageof 9